Simcere Pharma
VC Fund
Nanjing, China
Simcere Pharma is a VC fund in Nanjing focused on Biotechnology and Health Care. Founded on 28th March 1995, Simcere swiftly evolved from being a pure distributor of pharmaceutical products to become a leading manufacturer and supplier of drugs in China's rapidly growing pharmaceutical market. Simcere currently operates five GMP-certified manufacturing facilities, two nationwide sales and marketing subsidiaries, a researchand development center and manages over 4,000 employees. They are the first Chinese chemical and biological drug company to list on the New York Stock Exchange with IPO proceeds reaching US$ 261 million.
- Total investments:
- 10
- Last investment:
- Lead investor:
- 20%
Last updated:
For AI agents: llms.txt
Industries Simcere Pharma invests in
Stages Simcere Pharma invests in
Countries Simcere Pharma invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Jindong Zhou
|
|||
Jinsheng Ren
|
|||
Investment Focus
Industry
- Biotechnology 7 (70%)
- Health Care 5 (50%)
- Biopharma 4 (40%)
- Pharmaceutical 4 (40%)
- Medical 3 (30%)
Stage
- Series A 5 (50%)
- Series B 2 (20%)
- Post-IPO Equity 1 (10%)
- Venture - Series Unknown 1 (10%)
Country
- China 4 (40%)
- United States 3 (30%)
- Taiwan 1 (10%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Jindong Zhou
Executive Vice President
|
Executive Vice President | Total investments: 0 | Find email | |
|
Jinsheng Ren
Founder & Chairman
|
Founder & Chairman | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
AnDiConBio
|
developer of respiratory anti-infection drugs, offering high-potential, low-risk products like new anti-influenza and oral anti-new coronavirus. | $27.6M / Series A / Apr 29, 2024 | |
|
Cornris Biotech
|
Cornris Biotech is a pharmaceutical company that specializes in research and development related to brain-transmitting drugs. | Series A / Dec 11, 2023 | |
Ningdan new drug
|
Ningdan New Drug is a developer of new drugs for central nervous system diseases. | Series A / Feb 08, 2023 | |
NeuroDawn Pharmaceutical
|
NeuroDawn Pharmaceutical develops new drugs that are designed to treat central nervous system diseases. | $14.7M / Series A / Feb 08, 2023 | |
Carmine Therapeutics
|
Carmine Therapeutics develops a novel type of gene therapy that utilizes extracellular vesicles produced in the laboratory. | Series A / Oct 13, 2022 | |
|
NeuroDawn Pharmaceutical
|
NeuroDawn Pharmaceutical develops new drugs that are designed to treat central nervous system diseases. | $1.5M / Series A / Aug 23, 2021 | |
Sidi Diagnostics
|
Sidi Diagnostics is a medical technology company that focuses on new molecular diagnostic technologies. | $40M / Venture - Series Unknown / Mar 01, 2020 | |
Amwise Diagnostic
|
Amwise Diagnostic is a leader in precision medicine technology for cancer. Our patented genetic analysis technologies assist doctors and patients in determining the most appropriate individualized treatment strategy that has optimal treatment effectiveness and minimal treatment-related adverse events. | $10M / Series B / Feb 26, 2020 | |
Veritas Genetics
|
Veritas Genetics is a provider of a genetic testing platform intended to empower people to live healthier and longer. The company's genetic technology can detect a wider range of variations in a gene than are typically found in next-generation sequencing and offers a screening test for hereditary breast and ovarian cancer risk, enablingclinical researchers and physicians in order to make informed decisions. | $30M / Series B / Oct 17, 2016 | |
NextCure
|
NextCure is a biopharmaceutical company focused on discovering and developing next generation immuno-oncology-based drugs. The Company is applying its proprietary platforms and know-how to identify novel and biologically relevant targets and develop first-in-class immunotherapy products. | $2M / Post-IPO Equity |
Co-Investors
Alphamab Oncology
1 deal together
China Merchants Health
1 deal together
China Minsheng Investment Group
1 deal together
CICC Capital
1 deal together
Cowin Capital
1 deal together
Drug Farm
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Simcere Pharma invest in?
Simcere Pharma invests primarily in Biotechnology, Health Care and Biopharma startups, most often at Series A and Series B stage. Most of the 10 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Simcere Pharma?
Public channels for Simcere Pharma include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Simcere Pharma?
The team at Simcere Pharma includes Jindong Zhou (Executive Vice President) and Jinsheng Ren (Founder & Chairman). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
